Literature DB >> 34536385

Guideline-Recommended Lung Cancer Screening Adherence Is Superior With a Centralized Approach.

Harrison B Smith1, Ralph Ward2, Cassie Frazier3, Jonathan Angotti1, Nichole T Tanner4.   

Abstract

BACKGROUND: To recognize fully the benefit of lung cancer screening (LCS), annual adherence must approach the high levels seen in the National Lung Screening Trial. Emerging data suggest that annual adherence is poor and that a centralized approach to screening improves adherence. RESEARCH QUESTIONS: Do differences in adherence exist between a centralized and decentralized approach to LCS within a hybrid program and what are predictors of adherence? STUDY DESIGN AND METHODS: A retrospective evaluation of a single-center hybrid LCS program was conducted to compare outcomes including patient eligibility and adherence between the centralized and decentralized approaches. Patient demographics and outcomes were compared between those screened with a centralized and decentralized approach and between adherent and nonadherent patients using two-sample t tests, χ 2 tests, or analyses of variance, as appropriate. Annual adherence analysis was conducted using data from patients who remained eligible for screening with a baseline Lung CT Screening Reporting and Data System (Lung-RADS) score of 1 or 2. Logistic regression was used to estimate the association between adherence and the primary exposure, adjusting for potential confounders.
RESULTS: A cohort of 1,117 patients underwent baseline low-dose CT imaging. Two hundred eleven patients (19%) were ineligible by United States Preventative Services Task Force criteria and most (90%) were screened with the decentralized approach. After exclusions, 765 patients with Lung-RADS score of 1 or 2 remained eligible for annual screening. Overall adherence was 56%; however, adherence in the centralized program was 70%, compared with 41% with the decentralized approach (P < .001). Individuals screened in a decentralized approach were 73% less likely to be adherent (OR, 0.27; 95% CI, 0.19-0.37). A greater proportion of patients with three or more comorbidities were screened outside the centralized program.
INTERPRETATION: Those screened using a centralized approach were more likely to meet eligibility criteria for LCS and more likely to return for annual screening than those screened using a decentralized approach. Published by Elsevier Inc.

Entities:  

Keywords:  adherence; lung cancer; lung cancer screening; thoracic oncology

Mesh:

Year:  2021        PMID: 34536385     DOI: 10.1016/j.chest.2021.09.002

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  Racial Disparities in Adherence to Annual Lung Cancer Screening and Recommended Follow-Up Care: A Multicenter Cohort Study.

Authors:  Roger Y Kim; Katharine A Rendle; Nandita Mitra; Chelsea A Saia; Christine Neslund-Dudas; Robert T Greenlee; Andrea N Burnett-Hartman; Stacey A Honda; Michael J Simoff; Marilyn M Schapira; Jennifer M Croswell; Rafael Meza; Debra P Ritzwoller; Anil Vachani
Journal:  Ann Am Thorac Soc       Date:  2022-09

Review 2.  Extracellular Vesicles in Lung Cancer Metastasis and Their Clinical Applications.

Authors:  Michela Saviana; Giulia Romano; Patricia Le; Mario Acunzo; Patrick Nana-Sinkam
Journal:  Cancers (Basel)       Date:  2021-11-11       Impact factor: 6.639

3.  Using the Framework for Reporting Adaptations and Modifications-Expanded (FRAME) to study lung cancer screening adaptations in the Veterans Health Administration.

Authors:  Thomas E Strayer; Lucy B Spalluto; Abby Burns; Christopher J Lindsell; Claudia I Henschke; David F Yankelevitz; Drew Moghanaki; Robert S Dittus; Timothy J Vogus; Carolyn Audet; Sunil Kripalani; Christianne L Roumie; Jennifer A Lewis
Journal:  Res Sq       Date:  2022-08-08

4.  Addressing Lung Cancer Screening Disparities: What Does It Mean to Be Centralized?

Authors:  Eduardo R Núñez; Matthew Triplette
Journal:  Ann Am Thorac Soc       Date:  2022-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.